Naratriptan (AmergeĀ®) is a triptan drug developed by Glaxo Wellcome Inc. and is used for the treatment of migraine headaches. Naratriptan is available in 2.5mg tablets. It is a selective 5-hydroxytryptamine1 receptor subtype agonist. Naratriptan hydrochloride is chemically designated as N-methyl-3-( 1-methyl-4-piperidinyl)-1H-indole-5-ethanesulfonamide.
Some side effects of the drug include vision changes, tingling sensations, tiredness or weakness, upset stomach, dizziness, and warm/cold temperature sensations. The Food and Drug Administration (FDA) approved Amerge on February 11, 1998.

Amerge - Product information from Glaxo Wellcome, in Portable Document Format (PDF). (naratriptan hydrochloride)
Meta Description: [ This site serves as the homepage of GSK's corporate web site. ]
Amerge Consumer Information - FDA - Consumer FAQ in html format with a link to approved labeling in pdf format.
Meta Description: [ Consumer Information Sheet ]
DrugDigest: Naratriptan ( Amerge ) - Information on dosage, usage, side effects, interactions, and drug comparisons including generics when available.